Novartis Licenses mRNA Therapy From China's Abogen for Up to $7.8 Billion
The Swiss drugmaker pays $575 million upfront for the ABO2203 therapy, with up to $7.2 billion more tied to development milestones.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
4 publishers have covered this in 7 articles since 29 Sept 2026. STAT published first, on 29 September at 17:54 UTC; Latest from Tom's Hardware followed 41h 05m later. The most recent article, from Quartz, appeared on 2 October at 13:50 UTC.
Outlets reporting it: Bloomberg Markets (major outlet), STAT, Latest from Tom's Hardware, Quartz.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- STATSTAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
- STATSTAT+: Pharmalittle: We’re reading about Beam suing over IP theft, a Trump rule on importing meds, and more
- STATSTAT+: Three biotech updates, including accusations of theft and and a new lobbying leader
- Latest from Tom's HardwareMicron lawsuit claims Chinese memory maker YMTC poached its engineers, then sued it using its own stolen tech
- Bloomberg MarketsNovartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion
- QuartzNovartis is licensing an mRNA autoimmune therapy from China's Abogen for up to $7.8 billion
- QuartzNovartis lizenziert eine mRNA-Autoimmuntherapie von Chinas Abogen für bis zu 7,8 Milliarden US-Dollar.
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion Bloomberg Markets ·
- Novartis lizenziert eine mRNA-Autoimmuntherapie von Chinas Abogen für bis zu 7,8 Milliarden US-Dollar. Quartz
- Novartis is licensing an mRNA autoimmune therapy from China's Abogen for up to $7.8 billion Quartz
- Micron lawsuit claims Chinese memory maker YMTC poached its engineers, then sued it using its own stolen tech Latest from Tom's Hardware
- STAT+: Three biotech updates, including accusations of theft and and a new lobbying leader STAT
- STAT+: Pharmalittle: We’re reading about Beam suing over IP theft, a Trump rule on importing meds, and more STAT
- STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property STAT
In this story
- Novartis
- Abogen Biosciences